LIFEVANTAGE CORP Comprehensive Income
LIFEVANTAGE CORP (LFVN) reported Comprehensive Income of $4.37 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-27
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $1.14M, a 51.22% decline year-over-year.
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $1.24M, a 66.63% decline year-over-year.
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $17.00K, a 99.09% decline year-over-year.
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $1.98M, a 24.53% decline year-over-year.
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2026 was $4.37M, a 58.53% decline from fiscal 2025.
- LIFEVANTAGE CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $10.55M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $2.38M derived: sum of 2 quarters · filed 2026-08-27 | $2.40M derived: sum of 3 quarters · filed 2026-08-27 | $4.37M 10-K · filed 2026-08-27 |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-06 | $1.26M derived: sum of 2 quarters · filed 2026-05-06 | $3.24M 10-Q · filed 2026-05-06 | $5.57M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | $17.00K 10-Q · filed 2026-02-04 | $1.99M 10-Q · filed 2026-02-04 | $4.32M derived: sum of 3 quarters · filed 2026-08-27 | $8.05M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | $1.98M 10-Q · filed 2025-11-04 | $4.31M derived: sum of 2 quarters · filed 2026-08-27 | $8.03M derived: sum of 3 quarters · filed 2026-08-27 | $9.90M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $6.06M derived: sum of 2 quarters · filed 2026-08-27 | $7.93M derived: sum of 3 quarters · filed 2026-08-27 | $10.55M 10-K · filed 2026-08-27 |
| 2025-03-31 | $3.73M 10-Q · filed 2026-05-06 | $5.60M derived: sum of 2 quarters · filed 2026-05-06 | $8.21M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $1.87M 10-Q · filed 2026-02-04 | $4.49M 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $2.62M 10-Q · filed 2025-11-04 | |||
| 2024-03-31 | $1.13M 10-Q · filed 2025-05-06 | $937.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.27M 10-Q · filed 2025-05-06 | |
| 2023-12-31 | -$193.00K 10-Q · filed 2025-02-05 | $142.00K 10-Q · filed 2025-02-05 | ||
| 2023-09-30 | $335.00K 10-Q · filed 2024-10-29 | |||
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-02 | $618.00K derived: sum of 2 quarters · filed 2024-05-02 | $718.00K 10-Q · filed 2024-05-02 | |
| 2022-12-31 | -$418.00K 10-Q · filed 2024-01-30 | -$318.00K 10-Q · filed 2024-01-30 | ||
| 2022-09-30 | $100.00K 10-Q · filed 2023-11-09 | |||
| 2022-03-31 | $851.00K 10-Q · filed 2023-05-04 | $751.00K derived: sum of 2 quarters · filed 2023-05-04 | $3.93M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | -$100.00K 10-Q · filed 2023-02-02 | $3.08M 10-Q · filed 2023-02-02 | ||
| 2021-09-30 | $3.18M 10-Q · filed 2022-11-02 | |||
| 2021-03-31 | $1.28M 10-Q · filed 2022-05-03 | $5.34M derived: sum of 2 quarters · filed 2022-05-03 | $7.95M 10-Q · filed 2022-05-03 | |
| 2020-12-31 | $4.06M 10-Q · filed 2022-02-01 | $6.67M 10-Q · filed 2022-02-01 | ||
| 2020-09-30 | $2.61M 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | $1.66M 10-Q · filed 2021-04-29 | $5.95M derived: sum of 2 quarters · filed 2021-04-29 | $7.70M 10-Q · filed 2021-04-29 | |
| 2019-12-31 | $4.29M 10-Q · filed 2021-02-02 | $6.03M 10-Q · filed 2021-02-02 | ||
| 2019-09-30 | $1.75M 10-Q · filed 2020-11-03 | |||
| 2019-03-31 | $1.74M 10-Q · filed 2020-05-05 | $2.69M derived: sum of 2 quarters · filed 2020-05-05 | $3.48M 10-Q · filed 2020-05-05 | |
| 2018-12-31 | $950.00K 10-Q · filed 2020-01-28 | $1.74M 10-Q · filed 2020-01-28 | ||
| 2018-09-30 | $786.00K 10-Q · filed 2019-10-30 | |||
| 2018-03-31 | $1.73M 10-Q · filed 2019-05-01 | $2.10M derived: sum of 2 quarters · filed 2019-05-01 | $2.93M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $363.00K 10-Q · filed 2019-02-04 | $1.20M 10-Q · filed 2019-02-04 | ||
| 2017-09-30 | $837.00K 10-Q · filed 2018-11-01 | |||
| 2017-03-31 | $87.00K 10-Q · filed 2018-05-09 | $181.00K derived: sum of 2 quarters · filed 2018-05-09 | $1.45M 10-Q · filed 2018-05-09 | |
| 2016-12-31 | $94.00K 10-Q · filed 2018-02-07 | $1.36M 10-Q · filed 2018-02-07 | ||
| 2016-09-30 | $1.27M 10-Q · filed 2017-11-08 | |||
| 2016-03-31 | $1.10M 10-Q · filed 2017-05-10 | $2.71M derived: sum of 2 quarters · filed 2017-05-10 | $3.80M 10-Q · filed 2017-05-10 | |
| 2015-12-31 | $1.61M 10-Q · filed 2017-02-08 | $2.69M 10-Q · filed 2017-02-08 | ||
| 2015-09-30 | $1.08M 10-Q · filed 2016-12-12 | |||
| 2015-03-31 | $574.00K 10-Q/A · filed 2016-07-19 | $1.91M derived: sum of 2 quarters · filed 2016-07-19 | $6.68M 10-Q/A · filed 2016-07-19 | |
| 2014-12-31 | $1.34M 10-Q · filed 2016-02-09 | $6.11M 10-Q · filed 2016-02-09 | ||
| 2014-09-30 | $4.77M 10-Q · filed 2015-11-04 | |||
| 2014-03-31 | $2.60M 10-Q · filed 2015-05-06 | $5.69M derived: sum of 2 quarters · filed 2015-05-06 | $8.67M 10-Q · filed 2015-05-06 | |
| 2013-12-31 | $3.09M 10-Q · filed 2015-02-04 | $6.07M 10-Q · filed 2015-02-04 | ||
| 2013-09-30 | $2.98M 10-Q · filed 2014-11-06 | |||
| 2012-03-31 | -$4.93M 10-Q · filed 2012-05-15 | $7.65M 10-Q · filed 2012-05-15 | ||
| 2011-03-31 | -$9.78M 10-Q · filed 2012-05-15 | -$3.63M 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |